クライム・バイオ
Climb Bio, Inc.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.18 | $0 | -$11M |
| 2026 Q1 | -0.20 | $0 | -$14M |
| 2025 Q4 | -0.26 | $0 | -$16M |
| 2025 Q3 | -0.19 | $0 | -$12M |
| 2025 Q2 | -0.13 | $0 | -$11M |
| 2025 Q1 | -0.31 | $0 | -$15M |
| 2024 Q4 |
| -0.13 |
| $0 |
| -$6M |
| 2024 Q3 | -0.13 | $0 | -$8M |